Compare SMWB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMWB | STTK |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.6M | 538.3M |
| IPO Year | 2021 | 2020 |
| Metric | SMWB | STTK |
|---|---|---|
| Price | $6.35 | $7.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $4.00 | ★ $10.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $11.07 | N/A |
| Revenue Next Year | $11.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.22 | $0.71 |
| 52 Week High | $10.75 | $8.33 |
| Indicator | SMWB | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 58.96 |
| Support Level | $5.73 | $5.87 |
| Resistance Level | $7.84 | $7.64 |
| Average True Range (ATR) | 0.51 | 0.62 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 25.16 | 71.63 |
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.